Research progress and clinical application prospects of miRNAs in oral cancer

Xing, Long; Feng, Zhichun; Nie, Huan; Liu, Meitian; Liu, Yali; Zhang, Xiao-Hua; Zhou, Haijing

doi:10.1007/s11033-022-07604-w

Cited by 3 publications

(1 citation statement)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although progress has been made towards the identification of common miRNA expression profiles that influence oral cancer growth, metastasis and chemotherapeutic resistance, recent advances have suggested that additional non-coding miRNAs (such as miR-155 and miR-494) may be involved in multiple pathways more specifically related to chemotherapeutic responsiveness to Paclitaxel [ 16 , 17 ]. In addition, new research has revealed other miRNAs that may modulate chemotherapy resistance in oral cancers, such as miR-27 and Cisplatin resistance [ 18 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

Chemotherapeutic Drug Resistance Associated with Differential miRNA Expression of miR-375 and miR-27 among Oral Cancer Cell Lines

Huni

Cheung²,

Sullivan³

et al. 2023

IJMS

View full text Add to dashboard Cite

Recent advances have suggested that non-coding miRNAs (such as miR-21, miR-27, miR-145, miR-155, miR-365, miR-375 and miR-494) may be involved in multiple aspects of oral cancer chemotherapeutic responsiveness. This study evaluated whether these specific miRNAs are correlated with oral cancer responsiveness to chemotherapies, including Paclitaxel, Cisplatin and Fluorouracil (5FU). Commercially available and well-characterized oral squamous cell carcinoma cell lines (SCC4, SCC9, SCC15, SCC25 and CAL27) revealed differing resistance and chemosensitivity to these agents—with SCC9 and SCC25 demonstrating the most resistance to all chemotherapeutic agents. SCC9 and SCC25 were also the only cell lines that expressed miR-375, and were the only cell lines that did not express miR-27. In addition, the expression of miR-375 was associated with the upregulation of Rearranged L-myc fusion (RLF) and the downregulation of Centriolar protein B (POC1), whereas lack of miR-27 expression was associated with Nucleophosmin 1 (NPM1) expression. These data have revealed important regulatory pathways and mechanisms associated with oral cancer proliferation and resistance that must be explored in future studies of potential therapeutic interventions.

show abstract

Section: Introductionmentioning

confidence: 99%

Chemotherapeutic Drug Resistance Associated with Differential miRNA Expression of miR-375 and miR-27 among Oral Cancer Cell Lines

Huni

Cheung²,

Sullivan³

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

Comment on letters to the editor in oral oncology referring to microRNAs as therapeutic molecules for oral squamous cell carcinoma

et al. 2023

View full text Add to dashboard Cite

Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma

et al. 2022

View full text Add to dashboard Cite

Oral squamous cell carcinoma is the most common malignant epithelial neoplasm affecting the oral cavity. While surgical resection is the cornerstone of a multimodal curative approach, some tumors are deemed recurrent or metastatic (R/M) and often not suitable for curative surgery. This mainly occurs due to the extent of lesions or when surgery is expected to result in poor functional outcomes. Amongst the main non-surgical therapeutic options for oral squamous cell carcinoma are radiotherapy, chemotherapy, molecular targeted agents, and immunotherapy. Depending on the disease setting, these therapeutic approaches can be used isolated or in combination, with distinct efficacy and side effects. All these factors must be considered for treatment decisions within a multidisciplinary approach. The present article reviews the evidence regarding the treatment of patients with R/M oral squamous cell carcinoma. The main goal is to provide an overview of available treatment options and address future therapeutic perspectives.

show abstract

Research progress and clinical application prospects of miRNAs in oral cancer

Cited by 3 publications

References 109 publications

Chemotherapeutic Drug Resistance Associated with Differential miRNA Expression of miR-375 and miR-27 among Oral Cancer Cell Lines

Chemotherapeutic Drug Resistance Associated with Differential miRNA Expression of miR-375 and miR-27 among Oral Cancer Cell Lines

Comment on letters to the editor in oral oncology referring to microRNAs as therapeutic molecules for oral squamous cell carcinoma

Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma

Contact Info

Product

Resources

About